Clinical trials: Stage I Multiple Myeloma
Multiple Myeloma
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM
The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with isatuximab, and to establish the recommended Phase 2 dose (RP2D) for the combination treatment to explore in the cohort…
- Trial name
- NCT07217184
- Testing
- Belantamab mafodotin, Isatuximab
- Where
- 19 sites in United States, Australia and 9 more
- Volunteers
- 30 people
- Sponsor
- GlaxoSmithKline
Relapsed or Refractory Multiple Myeloma
A Study of QLS4131 in Patients With Recurrent or Refractory Multiple Myeloma
The purpose of this study is to characterize the safety of QLS4131 injection and to determine the recommended Phase 2 dose (RP2D) and to further evaluate the efficacy and safety of QLS4131 injection in participants with relapsed…
- Trial name
- NCT06500507
- Testing
- QLS4131 Injection
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Multiple Myeloma and Plasma Cell Neoplasm
Bortezomib, Ascorbic Acid, and Melphalan in Treating Patients With Newly Diagnosed Multiple Myeloma
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of cancer cells, either by…
- Trial name
- NCT00317811
- Testing
- ascorbic acid, bortezomib, melphalan
- Where
- 8 sites in United States
- Volunteers
- 35 people
- Sponsor
- Oncotherapeutics
Tumors, Lymphoma
Safety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent Malignancies (MK-8669-001 AM5)(COMPLETED)
Phase 1 trial to determine the safety, tolerability and maximum tolerated dose (MTD) of ridaforolimus in patients with refractory or recurrent malignancies, including myeloma and lymphoma.
- Conditions
- Tumors, Lymphoma, Multiple Myeloma
- Trial name
- NCT00060632
- Testing
- ridaforolimus
- Volunteers
- 46 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced or Refractory Leukemia, Lymphoma, Multiple Myeloma
Bioengineered Allogeneic Immune Cells (AlloStim) Not Requiring HLA Donor Match for Blood Cancers
This phase I/II clinical investigation is designed to determine the safety and anti-tumor effects of intravenous administration of the experimental immunotherapy drug, called AlloStim.
- Trial name
- NCT00861965
- Testing
- AlloStim-8
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Mirror Biologics, Inc.
Multiple Myeloma
Dasatinib in Combination With Revlimid (and Dexamethasone)
The purpose of this study was to determine the safety and tolerability of dasatinib when given in combination with lenalidomide and a low dose dexamethasone for the treatment of relapsed or refractory multiple myeloma.
- Trial name
- NCT00560391
- Testing
- Dasatinib, 70 mg + Lenalidomide, 15 mg + Dexamethasone, 40 mg, Dasatinib, 70 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg, Dasatinib, 100 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg
- Where
- 4 sites in United States, Australia and 1 more
- Volunteers
- 35 people
- Sponsor
- Bristol-Myers Squibb
Relapsed/Refractory Multiple Myeloma
Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM
The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with other anti-cancer treatments (in each sub-study), and to establish the recommended Phase 2 dose for each combination…
- Trial name
- NCT06655818
- Testing
- Belantamab Mafodotin, Dostarlimab
- Where
- 3 sites in France, South Korea
- Volunteers
- 4 people
- Sponsor
- GlaxoSmithKline
Multiple Myeloma, Refractory, Multiple Myeloma in Relapse
A Study to Investigate the Safety and Efficacy of TEG002 in Relapsed/Refractory Multiple Myeloma Patients
This is a single arm, open-label, multicenter phase I study to assess the safety, tolerability and preliminary efficacy of autologous T cells transduced with a specific γδTCR, i.e.
- Conditions
- Multiple Myeloma, Refractory, Multiple Myeloma in Relapse, Multiple Myeloma
- Trial name
- NCT04688853
- Testing
- TEG002
- Where
- 3 sites in United States
- Volunteers
- 26 people
- Sponsor
- Gadeta B.V.
Multiple Myeloma
A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma
This multicenter, open-label, dose-escalating study will assess the safety and efficacy of DFRF4539A in patients with relapsed or refractory multiple myeloma.
- Trial name
- NCT01432353
- Testing
- DFRF4539A
- Where
- 8 sites in United States
- Volunteers
- 39 people
- Sponsor
- Genentech, Inc.
Solid Tumor, Multiple Myeloma
Dose Escalation Trial of Dalotuzumab (MK-0646) in Advanced Solid Tumors and Multiple Myeloma (MK-0646-001)
This study will look for the highest tolerated dose of dalotuzumab (MK-0646) given as weekly, every other week. or a every three week infusion.
- Trial name
- NCT00701103
- Testing
- Dalotuzumab
- Volunteers
- 80 people
- Sponsor
- Merck Sharp & Dohme LLC
Multiple Myeloma
Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma
RATIONALE: Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00743288
- Testing
- Melphalan, Panobinostat
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Oncotherapeutics
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
A Trial of Selinexor, Ruxolitinib and Methylprednisolone
Selinexor, a first-in-class, oral selective exportin 1 (XPO1) inhibitor, has shown promise in pre-clinical and clinical studies.
- Trial name
- KPT-IST-391 (NCT06225310)
- Testing
- Selinexor, Ruxolitinib, Methylprednisolone
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Oncotherapeutics
Multiple Myeloma and Plasma Cell Neoplasm
Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Oblimersen may increase the effectiveness of dexamethasone by making cancer cells more sensitive to the…
- Trial name
- NCT00017602
- Testing
- oblimersen sodium, dexamethasone
- Where
- United States
- Sponsor
- Genta Incorporated
Neoplasms, Plasma Cell, Neoplasms by Histologic Type
A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
The is a first clinical study for Oricell Therapeutics Inc. in the United States to evaluate the safety, PK, PD and preliminary efficacy of our anti-GPRC5D cell product (OriCAR-017) in subjects with relapsed/refractory multiple…
- Conditions
- Neoplasms, Plasma Cell, Neoplasms by Histologic Type, Neoplasms, Hemostatic Disorders
- Trial name
- NCT06271252
- Testing
- OriCAR-017
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- OriCell Therapeutics Co., Ltd.
Multiple Myeloma (MM)
A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
The purpose of this study is to compare the pharmacokinetic (PK) similarity, safety, tolerability, immunogenicity, and efficacy of HLX15-SC versus US-DARZALEX FASPRO® following single and multiple subcutaneous (SC) injections in…
- Trial name
- NCT07477587
- Testing
- HLX15-SC-Rd, US-DARZALEX FASPRO®-Rd
- Where
- 84 sites in United States, Australia and 3 more
- Volunteers
- 258 people
- Sponsor
- Shanghai Henlius Biotech
Multiple Myeloma Stage I
Therapy With Zoledronic Acid in Patients With Multiple Myeloma Stage I
Multiple myeloma is a disease of B-lymphocytes producing malignant plasma cells. Malignant plasma cells induce osteolytic lesions, which is characteristic for progression of multiple myeloma.
- Trial name
- NCT00171925
- Testing
- Zoledronic acid, Calcium / Vitamin D
- Where
- Germany
- Volunteers
- 143 people
- Sponsor
- Novartis Pharmaceuticals
Relapsed or Refractory Non-Hodgkin's Lymphoma, Relapsed or Refractory Multiple Myeloma
Study of BEBT-908 in Subjects With Advanced Hematological Tumors
The purpose of this study was to evaluate the safety and tolerance of BEBT-908 for injection in the treatment of recurrent refractory malignant lymphoma, multiple myeloma and chronic lymphoblastic leukemia, and to obtain the…
- Trial name
- NCT06082596
- Testing
- BEBT-908 for injection
- Where
- China
- Volunteers
- 32 people
- Sponsor
- BeBetter Med Inc
Relapsed or Refractory Multiple Myeloma
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
This is an open-label, multicenter phase 1 clinical trial to evaluate the safety and tolerability, efficacy, and pharmacokinetics of SIM0500 in adult participants with Relapsed or Refractory Multiple Myeloma(RRMM).
- Trial name
- NCT06375044
- Testing
- SIM0500
- Where
- 16 sites in United States, China
- Volunteers
- 130 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Multiple Myeloma
BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma
The goal of this clinical trial is to study the feasibility and efficacy of anti-B-Cell Maturation Antigen (BCMA) expressing T cells in treating patients with multiple myeloma.
- Trial name
- NCT03943472
- Testing
- Anti-BCMA CAR-T cells, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Hrain Biotechnology Co., Ltd.
Multiple Myeloma
A Clinical Study of SHR-9539 in Patients With Multiple Myeloma
This study is a multicenter, open-label, dose-escalation/dose-expansion clinical Phase I trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy profile of SHR-9539 Injection in…
- Trial name
- NCT06484777
- Testing
- SHR-9539 for injection
- Where
- China
- Volunteers
- 138 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.